PubMed

Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes.

Chia CW, Carlson OD, Kim W, Shin YK, Charles CP, Kim HS, Melvin DL, Egan JM.

Diabetes. 2009 Jun;58(6):1342-9. Epub 2009 Mar 10.PMID: 19276444 [PubMed - indexed for MEDLINE]Related articlesFree article

The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.

Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ.

J Clin Endocrinol Metab. 2003 Oct;88(10):4897-903.PMID: 14557471 [PubMed - indexed for MEDLINE]Related articlesFree article

The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.

Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF, Andersen DK.

Regul Pept. 1994 Apr 14;51(1):63-74.PMID: 8036284 [PubMed - indexed for MEDLINE]Related articles

Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.

Højberg PV, Vilsbøll T, Zander M, Knop FK, Krarup T, Vølund A, Holst JJ, Madsbad S.

Diabet Med. 2008 Nov;25(11):1268-75.PMID: 19046215 [PubMed - indexed for MEDLINE]Related articles

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W.

J Clin Invest. 1993 Jan;91(1):301-7.PMID: 8423228 [PubMed - indexed for MEDLINE]Related articlesFree article

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

Diabetologia. 2002 Aug;45(8):1111-9. Epub 2002 Jul 4.PMID: 12189441 [PubMed - indexed for MEDLINE]Related articles

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W.

Diabetes Care. 1998 Nov;21(11):1925-31.PMID: 9802745 [PubMed - indexed for MEDLINE]Related articlesFree article

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

Regul Pept. 2003 Jul 15;114(2-3):115-21.PMID: 12832099 [PubMed - indexed for MEDLINE]Related articles

KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.

Aaboe K, Knop FK, Vilsboll T, Vølund A, Simonsen U, Deacon CF, Madsbad S, Holst JJ, Krarup T.

J Clin Endocrinol Metab. 2009 Feb;94(2):603-8. Epub 2008 Dec 2.PMID: 19050053 [PubMed - indexed for MEDLINE]Related articles

Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients.

Damci T, Yalin S, Balci H, Osar Z, Korugan U, Ozyazar M, Ilkova H.

Diabetes Care. 2004 May;27(5):1077-80.PMID: 15111524 [PubMed - indexed for MEDLINE]Related articlesFree article

Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.

Greenfield JR, Farooqi IS, Keogh JM, Henning E, Habib AM, Blackwood A, Reimann F, Holst JJ, Gribble FM.

Am J Clin Nutr. 2009 Jan;89(1):106-13. Epub 2008 Dec 3.PMID: 19056578 [PubMed - indexed for MEDLINE]Related articles

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA.

J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. Epub 2006 Aug 15.PMID: 16912128 [PubMed - indexed for MEDLINE]Related articlesFree article

Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.

Todd JF, Edwards CM, Ghatei MA, Mather HM, Bloom SR.

Clin Sci (Lond). 1998 Sep;95(3):325-9.PMID: 9730852 [PubMed - indexed for MEDLINE]Related articles

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ.

J Clin Endocrinol Metab. 2003 Jun;88(6):2706-13.PMID: 12788877 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of glucagon on carbohydrate-mediated secretion of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-36 amide) (GLP-1).

Ranganath L, Schaper F, Gama R, Morgan L, Wright J, Teale D, Marks V.

Diabetes Metab Res Rev. 1999 Nov-Dec;15(6):390-4.PMID: 10634963 [PubMed - indexed for MEDLINE]Related articles

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

Toft-Nielsen MB, Madsbad S, Holst JJ.

Diabetes Care. 1999 Jul;22(7):1137-43.PMID: 10388979 [PubMed - indexed for MEDLINE]Related articlesFree article

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W.

Diabetologia. 1993 Aug;36(8):741-4.PMID: 8405741 [PubMed - indexed for MEDLINE]Related articles

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.

Højberg PV, Vilsbøll T, Rabøl R, Knop FK, Bache M, Krarup T, Holst JJ, Madsbad S.

Diabetologia. 2009 Feb;52(2):199-207. Epub 2008 Nov 27.PMID: 19037628 [PubMed - indexed for MEDLINE]Related articles

Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects.

Chaikomin R, Doran S, Jones KL, Feinle-Bisset C, O'Donovan D, Rayner CK, Horowitz M.

Am J Physiol Endocrinol Metab. 2005 Sep;289(3):E504-7. Epub 2005 May 10.PMID: 15886226 [PubMed - indexed for MEDLINE]Related articlesFree article

Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.

Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ.

Diabetes. 2008 Mar;57(3):678-87. Epub 2007 Dec 5.PMID: 18057091 [PubMed - indexed for MEDLINE]Related articlesFree article